Clinical Endocrinology Laboratory
Major research areas
- The role of vitamin D deficiency in the pathogenesis of extraskeletal metabolic disorders in children and adults.
- Developing new drugs based on salts of succinic acid for the treatment of osteoporosis.
- Studying prognostic markers and differential diagnosis of various types of amiodarone-induced thyrotoxicosis.
- Studying the role of kisspeptins in the genesis of delayed sexual development in boys of puberty age.
- Studying the incidence of parathyroid gland disease and impaired cardiovascular remodeling in hypo- and hyperparathyroidism.
- Conducting clamp studies in healthy volunteers and type 1 diabetic patients.
- These studies have been conducted since 2012. The researchers of the Centre have established the contribution of vitamin D deficiency and individual polymorphisms of the vitamin D receptor gene to the development of certain components of the metabolic syndrome. The studies are ongoing to evaluate the role of vitamin D in children and adults with obesity and diabetes. Supraphysiological doses of vitamin D have been shown to have a positive effect on the indicators of microcirculation and inflammation in patients with type 2 diabetes and diabetic neuropathy. The specialists of the Centre co-authored the clinical guidelines for the diagnosis, prevention and treatment of vitamin D deficiency in adults and the National Programme “Vitamin D deficiency in children and adolescents of the Russian Federation: modern approaches to correction” proposed by the Russian Association of Endocrinologists, the Russian Association of Pediatricians and the Russian Association for Osteoporosis. The results of research in this area are presented annually at Russian and international congresses, including ECE, EASD, ADA, ESPE, WCO-IOF-ESCEO.
- Researchers continue their efforts on creating a novel drug for the treatment of osteoporosis based on salts of succinic acid. The results of preclinical trials have demonstrated efficacy and non-toxicity of this drug. A clinical and experimental study is conducted to examine the mechanisms of bone remodeling disorders in hyperglycemia and the effect of various types of sugar-lowering drugs. Jointly with the specialists of the Laboratory for Surgery for Metabolic Disorders, the researchers are studying the effect of various types of bariatric surgery on bone remodeling markers.
- Following the State Assignment for 2018—2020, the researchers have been searching for differential diagnostic criteria for types 1 and 2 amiodarone-induced thyrotoxicosis and an automated decision-making system is being developed.
- Based on clinical and experimental studies, kisspeptin mechanisms of sex regulation are studied and new techniques for treating sexual development disorders are being developed.
- The Centre has all the facilities for advanced examination and comprehensive treatment of patients with parathyroid gland disease. It is not only a leading medical facility providing medical care for patients with hypo- and hyperparathyroidism, but also a scientific centre conducting research in this field.
- Within the framework of the memorandum on cooperation, the specialists of the Research Laboratory use the hyperinsulinemic-euglycemic clamps (phase 1 study) in patients with type 1 DM and healthy volunteers using domestic biosimilar insulins of various durations. Based on the experience gained in this type of clinical research, Almazov Centre can be classified as one of the leading institutions in Russia that conduct clamp studies of various complexity.
Training and education
The specialists of the Research Laboratory take part in delivering advanced training courses for doctors and are actively involved in the implementation of educational programs for clinical residents and PhD students in the Endocrinology specialty.
Participation in State Assignments
- “Assessment of the safety and specificity of a new drug for the treatment and prevention of osteoporosis” (2018–2020)
- “Study of the mechanisms of cardiovascular damage in hypo- and hyperparathyroidism in order to develop a comprehensive personalized approach to examination and treatment” (2020–2022).
- “Long-term effects of vitamin D deficiency: a personalized approach to the prevention and treatment of cardiovascular and metabolic diseases” (2018–2020).
- “Molecular genetic predictors of the effects of vitamin D deficiency and their role in the development of socially significant diseases” (2015–2017).
The specialists of the Research Laboratory are involved in research under grant from the Russian Science Foundation No. 17-75-30052 on the topic “Development of personalized therapy for obesity and type 2 diabetes mellitus in order to reduce cardiovascular risks” (2017–2020, supervisor: Professor E.V. Shlyakhto).
Soboleva A., Mavropulo-Stolyarenko G., Karonova T., Thieme D., Hoehenwarter W., Ihling C., Stefanov V, Grishina T., Frolov A. Multiple glycation sites in blood plasma proteins as an integrated biomarker of type 2 diabetes mellitus. Int. J. Mol. Sci. 2019. Vol.20, №9 p.2329. doi:10.3390/ijms20092329. ИФ 4,1
Simanenkova A.V., Filchenko I.A., Chefu S.G., Shlyakhto E.V., Vlasov T.D. Neuroprotective action of liraglutide in experimental brain ischemia is independent on its influence on glucose metabolism. Diabetologia. 2019. Vol. 62. Suppl. 1. P. 521-522. ИФ 7,113
Karonova T, Grineva E, Belyaeva O, Bystrova A, Jude EB, Andreeva A, Kostareva A and Pludowski P. Relationship Between Vitamin D Status and Vitamin D Receptor Gene Polymorphisms With Markers of Metabolic Syndrome Among Adults. Front. Endocrinol.2018 Vol.9. doi: 10.3389/fendo.2018.00448 . ИФ 3,519
Karonova T., Tsiberkin A., Andreeva A., Grineva E., Belyaeva O., Jude E.B., Pludowski P. Serum 25 (OH) D and adipokines levels in people with abdominal obesity. The Journal of Steroid Biochemistry and Molecular Biology. 2018. Vol.175. P.170-176. DOI: 10.1016/j.jsbmb.2016.09.005 ИФ 3,785
Filchenko, A. Simanenkova, S. Chefu, M. Kolpakova, T. Vlasov. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats. Diabetes & Vascular Disease Research. 2018. Vol. 15. №6. 1–4. DOI: 10.1177/1479164118788079. ИФ 2,4
Patent No. 2560345 “Method for predicting the risk of developing metabolic syndrome in patients with abdominal obesity”
Authors: T.L. Karonova, O.A. Berkovich, O.D. Belyaeva, E.A. Chubenko, A.V. Berezina, E.I. Baranova
Patent No. 2582973 C1 “Anti-osteoporotic drug”
Authors: A.A. Bayramov, P.D. Shabanov, E.I. Maevsky, E.N. Grineva, E.V. Shlyakhto
Patent No. 2016120268A “Anti-osteoporotic drug”
Authors: A.A. Bayramov, P.D. Shabanov, R.A. Bayramov
Tatyana Karonova, Chief Researcher